Eric Chang MD

@JohnsHopkins - @UVMLarnerMed - @MSMEDU - @MSMEDU Cardiology - @TempleCards IC

[Lewis Katz School of Medicine @katztemplemed]

#TempleMed is proud to share that the BASHIR™ Endovascular Catheter (@ThrombolexTM), co-invented by our own @RiyazBashir, has been approved by the FDA for the treatment of acute pulmonary embolism. https://t.co/0YV62NaA3G

[Temple Health News @TempleMedNews]

The Bashir Endovascular Catheter, invented @templemedschool and developed @ThrombolexTM, has been approved by the @US_FDA for treatment of acute pulmonary embolism. Dr. @RiyazBashir, of @TempleHealth, is a co-inventor. Read more about the news here: https://t.co/0iubCXRFR5

[Eric Chang MD @EricYChang01]

An important concept that we sometimes neglect!
#Fellows2023

[Dipti Itchhaporia, M.D., MACC , FAHA, FESC @ditchhaporia]

Great being with all the @MSMEDU cardiology fellows-what a great group @EricYChang01 @ACCinTouch @ACC_Georgia #Cardiology #healthequity

[Eric Chang MD @EricYChang01]

Excited to be at #Fellows2023 !! What a fun event ;)

[Eric Chang MD @EricYChang01]

Great insights on the importance of shifting from sick care to health care. More focus is needed on addressing health inequities, social determinants of health, and Healthcare delivery.
@ditchhaporia

[Riyaz Bashir @RiyazBashir]

From @jaccjournals https://t.co/LZHKXpKvYE. Results of refined Balloon pulmonary angioplasty in US are very similar to those from Japan and Europe in CTEPH patients. @VladLakhter @SauravChMD @krosenfieldMD @anjalivaidyaMD @CarlosMRomeroMD @PForfiaPHDOC

[Marinos Charalambous @MarinosChar]

Excellent conference so far! Nice to be back in DC @CRT_meeting with @VladLakhter and @EricYChang01

[Geoff Barnes @GBarnesMD]

When I was in training, we used to think rate and rhythm control were “equal” for #cvAFib. We now know that rhythm control has significant benefits! #BackToHeart22

[Ilya Shadrin, MD/PhD @iShadrinMDPhD]

Fantastic presentation by @JonPicciniSr discussing 4 pillars of #afib management, including importance of rhythm control. STALL- HF showing an impressively high prevalence (65%) of HFpEF in afib patients. Ongoing CHANGE-AF trial assessing dronaderone in new afib. #BackToHeart22

[MedscapeLIVE @MedscapeLIVE]

🫀Here and ready for all things Cardiology! #backtoheart22 @EricYChang01 @DBelardoMD @drburgwontstop @AlokPatelMD

[Eric Chang MD @EricYChang01]

Inspiring story of sudden cardiac death, survival, and recovery. Importance of proper #cpr and cardiac rehab.
#BackToHeart22

[Eric Chang MD @EricYChang01]

Time to get back to the heart!
#BackToHeart22

[Eric Chang MD @EricYChang01]

Importance of familial hypercholesterolemia awareness! #BackToHeart22

[Medscape Education @MedscapeCME]

📍Mark your calendar for #BackToHeart22 : December 3-5, 2022 for our 3rd Annual Going Back to the Heart of Cardiology Conference presented live at the Hilton La Jolla Torrey Pines in San Diego, CA. #CardioTwitter https://t.co/ve70Qp7v39

[theheartorg | Medscape @theheartorg]

➡ CHALLENGE TIME: Join us December 3rd, 2022 for the New Interventional Virtual Session 🆕 Cath Lab Challenge at #BackToHeart22 Secure your spot today: https://t.co/SHyzUGjoBz #CardioTwitter

[Gina Lundberg MD FACC FAHA FNLA @gina_lundberg]

Great competition between #ACCFITJeopardy from @MSMEDU @AUG_University @emoryheart at #GAACC2022 @ACC_Georgia @MCGCardFellows @emory_heart @IncHeartKG @pascha_schafer @Allison_Dupont

[American College of Cardiology @ACCinTouch]

Who else is excited for #ACCLegConf 2022 to kick off today? ✋

The #ACCAdvocacy team is ready to welcome everyone to Washington, DC and dive into #healthpolicy issues. Make sure you're also following @Cardiology for the best updates.

🔎 Resources: https://t.co/tIpSzOl7Mm